Aspire Biopharma Holdings, Inc. sets 1-for-30 reverse split for Monday, May 11, 2026

Listing RiskvolatileImpact78

ASBP Price

Stored market data

$7.14-$0.07 (-0.97%)

Previous close $7.21Latest volume 1.2K

Why It Matters

Holders will see share counts cut 30-to-1, unchanged pro rata ownership but materially lower tradable float, higher per-share price, and elevated short-term trading risk.

Summary

Add Stock Radar as a preferred source on GoogleAdd Stock Radar on Google

Existing holders will own proportionally the same economic interest but hold far fewer shares, with likely reduced trading liquidity, wider spreads, and potential fractional-share cash-outs.

Score78

Score Rationale

volatile

1-for-30 reverse split dramatically reduces float and liquidity, raising volatility risk.

Bullish

Higher per-share price may regain compliance with minimum bid rules
Fewer outstanding shares can reduce free-float volatility over time
May make the stock eligible for some institutional or exchange thresholds

Bearish

Trading liquidity and daily volume likely fall sharply post-split
Wider bid-ask spreads and price volatility expected around effective date
Fractional-share cash settlements can produce small cash losses for holders
Reverse splits can signal weakness, attracting selling pressure

Key Evidence

Nasdaq alert: 1-for-30 reverse split effective 2026-05-11
Pre-split market data: ~$5.83 price, ~115k shares outstanding, tiny market cap

What To Watch Next

Company filing for fractional-share treatment and cash-out terms
Post-split outstanding share count and updated float
Trading volume, spreads and price action on and after 2026-05-11
Any disclosure about delisting risk or compliance reasons

AdvertisementResponsive display

Biotechnology Market Context

SectorHealthcare+0.70%

IndustryBiotechnology-1.26%